Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D...
-
Upload
benjamin-townsend -
Category
Documents
-
view
213 -
download
0
Transcript of Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D...
![Page 1: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/1.jpg)
Managing the Money Trail
in the Research Environment
Seth B. Whitelaw
Compliance Officer, Global R&D
GlaxoSmithKline14 November 2002
![Page 2: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/2.jpg)
2
The Business Objective
Obtain the best possible data, in the shortest amount of
time
![Page 3: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/3.jpg)
3
The Challenges
Managing the process to avoid compromises in patient safety, data integrity or engaging in commercial bribery
Demonstrating to the public, regulators, shareholders that the concern is understood and being addressed 24/7
![Page 4: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/4.jpg)
4
Some Possible IncomeSources for Clinicians
Clinical Trial Work
Speaking Fees
Advisory Boards
IP
![Page 5: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/5.jpg)
5
New Developments
TAP Pharmaceuticals Case
OIG Compliance Program Guidance
PhRMA Principles (Heather Stewart)
Post-marketing Studies (Heather Stewart)
![Page 6: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/6.jpg)
6
TAP Pharmaceuticals
Settlement of $875M
Criminal indictments
Corporate Integrity Agreement (7 years)
– Educational Grants
– Research Grants
– Consulting and advising arrangements
![Page 7: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/7.jpg)
7
OIG Compliance Program Guidance:Risk Areas
Consultants and advisors
Grants for research and education
Gifts and gratuities
Vendors and other agents
![Page 8: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/8.jpg)
8
OIG CPG: Risk Areas (cont’d)
Consultants and advisors– Research, data collection, advisory boards, focus
groups, speakers
– Compensation only for “actual, reasonable and necessary services” not “token arrangements created to disguise otherwise improper payments.”
– Manufacturers should “ensure appropriate documentation of the fair market value determination, as well as the performance of the services.”
![Page 9: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/9.jpg)
9
OIG CPG: Risk Areas (cont’d)
Grants for research and education– Particular risk “where they involve parties in a position to
prescribe or order the manufacturer’s product …”
Gifts and gratuities– Must not exceed nominal value and not exceed fair
market value for services rendered
– Does not take “into account, directly or indirectly, the volume or value of business generated”
![Page 10: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/10.jpg)
10
OIG CPG: Risk Areas (cont’d)
Vendors and other agents – CO should “ensur[e] that independent contractors and
agents … are aware of company’s compliance program …”
![Page 11: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/11.jpg)
11
OIG CPG: Compliance Activities
Education and training– OIG considers this to be a “must” do
– Specific training on risk areas (those in guidance and those identified by other means) for employees associated with relevant activities
– New employee and refresher training is important; failure to attend should result in disciplinary action; should be part of employee evaluation
![Page 12: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/12.jpg)
12
OIG CPG: Compliance Activities (cont’d)
Auditing and Monitoring– Flexibility on frequency and subject of audits; could be
prospective or retrospective
– Use of “internal or external evaluators who have relevant expertise”
Mechanisms for corrective action– Duty to investigate “reasonable indications of suspected
noncompliance”
![Page 13: Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.](https://reader035.fdocuments.net/reader035/viewer/2022070400/56649f145503460f94c29918/html5/thumbnails/13.jpg)
13
What Does the Future Hold? Pressure to achieve the business
objective will increase.
The challenges will remain and grow more acute.
The demand for accountability will increase and become global.
.
The need for compliance programs tailored to the research
environment will increase.